News and Events
21st century anti-histamines for treating diabetic kidney disease
(15 January 2018)
Currently, renal dialysis and transplant are the only options for treatment. In the last few years new and growing evidence on the possible role of histamine in diabetes has been provided by the groups of Drs Paul Chazot in Durham University's Department of Biosciences and Arianna Rosa (University of Turin). In particular, the histamine receptor H4R is emerging as a new promising pharmacological target for diabetic nephropathy. The aim of this study was to evaluate the efficacy of selective H4R antagonism using a clinical-lead drug on the prevention of diabetic nephropathy progression in a murine model of type-1 diabetes . Our data suggest for the first time that the H4R participates in diabetic nephropathy progression through both a direct effect on tubular reabsorption and an indirect action on renal tissue architecture via inflammatory cell recruitment. Therefore, H4R antagonism emerges as a possible new multi-mechanism therapeutic approach to counteract development of diabetic nephropathy development. Published in
Pharmacological Research (2018) 128: 18-28.